Meggle Receives EXCiPACT Certification - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Meggle Receives EXCiPACT Certification


Meggle Group Wasserburg announced that it has been granted an EXCiPACT certificate. Following an inspection on the company’s manufacturing processes, quality systems, quality management, storage and distribution of pharmaceutical grade lactose, and its associated auxiliary materials used in the production process, auditors from the certifying body SGS (Société Générale de Surveillance, Hamburg, Germany) have confirmed that the Meggle Business Group Excipients & Technology complies with the quality standards of good manufacturing and good distribution practices (GMP & GDP) for its pharmaceutical excipients.

The EXCiPACT certification assures optimal product quality and security within the supply chain as a means to protect patient safety and ensure efficient cost. Since its introduction in 2013, the EXCiPACT certificate has been granted only to a dozen companies. The certificate documents the high standard to which Meggle has committed. For many years, the company has operated according to the international industrial GMP/GDP standard and ISO norms.

The quality standards as defined in EXCiPACT are specifically for manufacturing and supply of pharmaceutical excipients. To ensure compliance with the standards, and consequently for the patient safety, the certificate holders are reviewed annually and re-audited every three years.

Source: Meggle

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications

Click here